BodyScan Corp. (BDYS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBodyScan Corp. (BDYS) trades at $0.00002. BodyScan Corp. specializes in advanced medical diagnostic imaging, utilizing state-of-the-art GE-Imatron Electron Beam Tomography (EBT) technology. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for BDYS: BDYS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
BodyScan Corp. (BDYS) Healthcare & Pipeline Overview
BodyScan Corp., based in Irvine, California, provides advanced medical diagnostic imaging services. Leveraging state-of-the-art GE-Imatron Electron Beam Tomography (EBT) technology, the company focuses on early detection of critical conditions such as coronary artery disease, pulmonary diseases, and various neoplastic growths, positioning itself in the specialized diagnostic healthcare segment.
What Is the Investment Thesis for BDYS?
BodyScan Corp. operates in the critical and growing medical diagnostic imaging sector, leveraging specialized GE-Imatron Electron Beam Tomography (EBT) technology. The core investment thesis revolves around the increasing global demand for early and precise detection of life-threatening conditions such as coronary artery disease, various pulmonary ailments, and neoplastic growths, where EBT offers high-resolution, non-invasive diagnostic capabilities. The broader medical imaging market is projected for sustained growth, fueled by an aging population, rising prevalence of chronic diseases, and a heightened emphasis on preventive care. BodyScan's niche specialization positions it to capture a segment of this expanding demand by providing highly accurate diagnostic insights. However, the company's listing on the OTC Other tier and its extremely low share price signal substantial financial and operational risks, including potential challenges in securing adequate funding for expansion, achieving consistent profitability, and navigating market perception. Future value drivers would include demonstrated growth in patient volumes, successful expansion of its imaging center footprint, strategic partnerships within the healthcare ecosystem, or improved financial transparency. Investors must carefully monitor operational efficiency, any progress in market tier, and the company's ability to sustain operations and achieve profitability, acknowledging the inherent high-risk, high-reward profile associated with its current market status.
Based on FMP financials and quantitative analysis
BDYS Key Highlights
Specialization in state-of-the-art GE-Imatron Electron Beam Tomography (EBT) technology for advanced diagnostic imaging.
- Primary focus on the early detection of critical conditions including coronary artery disease, various pulmonary ailments, and neoplastic growths.
- Operates within the specialized medical care facilities segment of the healthcare sector, addressing a growing need for precise diagnostics.
- Trades on the OTC Other tier, indicating a high-risk, low-disclosure environment for investors.
- Does not currently pay a dividend, reflecting a potential focus on reinvestment or limited current profitability.
Who Are BDYS's Competitors?
BDYS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| HCA HCA Healthcare, Inc. | $426.69 | +0.78% | $92.4B | 82 5-pillar |
| THC Tenet Healthcare Corporation | $258.62 | +1.83% | $20.8B | 89 5-pillar |
| SOLV Solventum Corporation | $87.85 | +0.09% | $15.2B | 61 5-pillar |
| FMS Fresenius Medical Care AG & Co. KGaA | $22.25 | -0.02% | $12.0B | 83 5-pillar |
| EHC Encompass Health Corporation | $119.80 | +0.62% | $11.9B | 90 5-pillar |
| DVA DaVita Inc. | $178.69 | +1.33% | $11.5B | 75 5-pillar |
| UHS Universal Health Services, Inc. | $175.72 | +0.37% | $10.6B | 94 5-pillar |
| ENSG The Ensign Group, Inc. | $171.78 | +1.27% | $10.0B | 75 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BDYS's Key Strengths?
Specialized GE-Imatron EBT technology for precise, non-invasive diagnostics.
- Focus on early detection of critical conditions (CAD, pulmonary ailments, neoplastic growths).
- Operates in the growing medical diagnostic imaging sector with increasing demand for preventive care.
- Headquartered in Irvine, California, a region known for healthcare innovation.
What Are BDYS's Weaknesses?
OTC Other tier listing indicates substantial financial and operational risks and limited transparency.
- Extremely low share price suggests market skepticism, potential liquidity issues, and difficulty in capital raising.
- "Unknown" disclosure status implies limited public financial information, hindering investor due diligence.
- Reliance on a single, specialized technology (EBT) could limit diagnostic breadth compared to multi-modality centers.
What Are the Key Risks for BDYS?
Significant financial and operational risks associated with its OTC Other tier listing and extremely low share price.
- Inability to secure adequate funding or capital for sustained operations, technological upgrades, or planned expansion initiatives.
- Intense competition from larger, more established diagnostic imaging providers with broader service offerings and greater resources.
- Adverse regulatory changes or shifts in healthcare reimbursement policies that could negatively impact diagnostic imaging services.
- Limited public disclosure and transparency, making it challenging for investors to accurately assess the company's financial health and strategic direction.
What Threats Does BDYS Face?
- Intense competition from larger, multi-modality diagnostic centers and hospital networks.
- Potential for regulatory changes in healthcare or reimbursement policies impacting diagnostic imaging services.
- Risk of technological obsolescence if EBT is surpassed by newer, more cost-effective, or superior diagnostic methods.
- Significant capital constraints and challenges in securing funding as an OTC Other company.
- Negative market perception and difficulty attracting institutional investment due to OTC status and low share price.
What Are BDYS's Competitive Advantages?
- Specialized GE-Imatron Electron Beam Tomography (EBT) technology, which may not be widely available in all diagnostic centers.
- Expertise in interpreting EBT scans for specific conditions like CAD, pulmonary ailments, and neoplastic growths.
- Focus on early detection and preventive healthcare, offering a distinct value proposition in a growing market segment.
- Established operational presence in Irvine, California, potentially with existing local referral networks and patient base.
What Does BDYS Do?
Based in Irvine, California, BodyScan Corp. is a specialized provider of advanced medical diagnostic imaging services, operating within the critical healthcare sector. The company distinguishes itself by exclusively utilizing state-of-the-art GE-Imatron Electron Beam Tomography (EBT) technology. This highly sophisticated imaging modality is central to BodyScan's mission of offering precise and non-invasive detection capabilities for a range of serious medical conditions. Specifically, BodyScan's EBT scans are employed for the early identification of coronary artery disease (CAD), a leading cause of mortality globally, by detecting calcification in the coronary arteries. Beyond cardiovascular health, the company's services extend to the detection of various pulmonary ailments, such as lung nodules, which are crucial for early intervention in respiratory diseases. Furthermore, BodyScan plays a vital role in oncology by screening for neoplastic growths, or tumors, enabling earlier diagnosis and potentially more effective treatment strategies. The technology is also adept at identifying calculi, such as kidney stones. By focusing on these specific, high-impact diagnostic areas, BodyScan Corp. positions itself as a critical resource for patients and referring physicians seeking highly accurate and timely diagnostic information. The company's operational model is centered around its dedicated imaging facilities, where skilled technicians and medical professionals conduct and interpret these advanced scans, contributing significantly to preventive healthcare and improved patient outcomes through early disease detection.
What Products and Services Does BDYS Offer?
- Provides advanced medical diagnostic imaging services.
- Utilizes state-of-the-art GE-Imatron Electron Beam Tomography (EBT) technology.
- Detects coronary artery disease (CAD) in its early stages through calcium scoring.
- Identifies various pulmonary ailments, such as lung nodules, for early intervention.
- Screens for neoplastic growths, including tumors, aiding in cancer detection.
- Detects calculi, such as kidney stones, for timely diagnosis and management.
- Aims to provide precise, non-invasive diagnostic information to improve patient outcomes.
- Operates from its dedicated imaging facility located in Irvine, California.
How Does BDYS Make Money?
- Generates revenue by performing specialized medical diagnostic scans using EBT technology.
- Services are likely billed to patients directly, through private insurance providers, or via healthcare networks.
- Focuses on high-resolution imaging for early disease detection, offering a value proposition in preventive care.
- Operates dedicated imaging centers equipped with advanced GE-Imatron EBT machines and trained personnel.
What Industry Does BDYS Operate In?
BodyScan Corp. is positioned within the dynamic and essential medical diagnostic imaging industry, a cornerstone of the global healthcare sector. This industry is experiencing robust growth, driven by several macro trends including an aging global population, the increasing prevalence of chronic diseases, and a pervasive shift towards preventive medicine and early disease detection. The market for advanced diagnostic modalities, encompassing technologies like CT, MRI, and specialized EBT, is expanding as healthcare providers and patients increasingly seek non-invasive yet highly accurate tools for diagnosis. BodyScan's specific niche involves the utilization of GE-Imatron Electron Beam Tomography (EBT), which offers distinct advantages in precision for detecting conditions such as coronary artery disease and certain cancers. While the company competes with larger, more diversified diagnostic imaging centers and hospital networks that offer a broader spectrum of imaging services, BodyScan differentiates itself through its specialized EBT focus, aiming for superior accuracy in its targeted applications. The overarching industry trend favors technologies that enhance diagnostic accuracy, improve patient outcomes, and support proactive health management.
Who Are BDYS's Key Customers?
- Patients seeking advanced diagnostic screenings for cardiovascular, pulmonary, or cancer-related concerns.
- Referring physicians, including cardiologists, pulmonologists, oncologists, and primary care doctors.
- Potentially healthcare networks or insurance providers through contractual agreements for diagnostic services.
- Individuals proactively managing their health and seeking early detection of critical conditions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
BodyScan Corp. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Jeffrey Volpe. BDYS has traded publicly since 2003.
BDYS Latest News
No recent news available for BDYS.
BDYS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BDYS.
Price Targets
Wall Street price target analysis for BDYS.
BDYS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BDYS; grades run from A+ (80-100) to F (below 30).
BDYS OTC Market Information
The OTC Other tier, where BodyScan Corp. (BDYS) currently trades, represents the lowest and most speculative segment of the over-the-counter market. Unlike companies listed on major exchanges such as NYSE or NASDAQ, which are subject to stringent listing standards regarding financial health, corporate governance, and minimum share prices, OTC Other companies face minimal disclosure requirements. This tier typically includes shell companies, defunct entities, or those with very limited public information. Trading in this segment is often characterized by extreme volatility and a high degree of risk, as investors have very little verifiable data to base investment decisions on, making it suitable only for investors with a high-risk tolerance.
- OTC Tier: OTC Other
- Limited transparency and availability of reliable financial information due to minimal disclosure requirements.
- Extreme price volatility and potential for market manipulation due to low trading volumes and limited oversight.
- Significant challenges in raising capital or securing financing for operations and growth initiatives.
- Difficulty in obtaining current and comprehensive company updates, hindering informed investment decisions.
- Increased risk of delisting or the company becoming a defunct entity, potentially leading to a complete loss of investment.
- Verify any available financial statements and audit reports, scrutinizing their recency and completeness.
- Research management's background, experience, and track record beyond publicly stated information.
- Assess the company's current operational status, actual revenue generation, and patient volumes.
- Investigate any legal or regulatory actions, past or present, against the company or its leadership.
- Examine historical trading volume and bid-ask spread to gauge actual liquidity and transaction costs.
- Seek independent verification of its EBT technology, operational facilities, and service quality.
- Understand the competitive landscape within medical diagnostic imaging and BodyScan's specific market position.
- Presence of a named CEO, Jeffrey Volpe, indicating active leadership.
- Specific business description focusing on advanced medical diagnostic imaging, suggesting a defined operation.
- Mention of state-of-the-art GE-Imatron Electron Beam Tomography (EBT) technology, implying a tangible asset.
- Headquarters located in Irvine, California, a known hub for healthcare and technology companies.
- Specialization in detecting specific medical conditions (CAD, pulmonary ailments, neoplastic growths, calculi), indicating a clear service offering.
BDYS Healthcare Stock FAQ
What are the primary challenges BodyScan Corp. faces operating on the OTC Other market?
BodyScan Corp. faces several primary challenges operating on the OTC Other market. This tier is characterized by minimal disclosure requirements, leading to a lack of readily available and audited financial information, which makes it difficult for investors to assess the company's true financial health and operational performance.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data provided.